Skip to Main Content
Home
Search
Study Topics
Glossary
Full Text View
Tabular View
No Study Results Posted
Related Studies
A Follow-up Study to Assess Safety and Tolerability of Galantamine Treatment in Individuals With Mild Cognitive Impairment
This study has been completed.
Study NCT00240695 Information provided by Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
First Received: October 14, 2005 Last Updated: March 17, 2008
History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Nervous System Diseases
Brain Diseases
Cognition Disorder
Mental Disorders
Additional conditions recognized in this trial
Cognition Disorders
Disease
More general conditions related to this trial
Central Nervous System Diseases
Delirium, Dementia, Amnestic, Cognitive Disorders
Pathologic Processes
Interventions listed in this trial
galantamine hydrobromide
Additional drug interventions recognized in this trial
Galantamine
More general drug interventions related to this trial
Autonomic Agents
Central Nervous System Agents
Cholinergic Agents
Cholinesterase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Neurotransmitter Agents
Nootropic Agents
Parasympathomimetics
Peripheral Nervous System Agents
Pharmacologic Actions
Physiological Effects of Drugs
Therapeutic Uses
Sponsors listed in this trial
Johnson &Johnson Pharmaceutical Research &Development, L.L.C.
Back to top of Main Content
